| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE | By: Brett Budzinski, Attorney-in-Fact For: Kevin Fitzgerald | 19 Aug 2025 | 0001886431 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ALNY | Common Stock | Award | $0 | +2,851 | +13% | $0.000000 | 24,115 | 15 Aug 2025 | Direct | F1 |
| transaction | ALNY | Common Stock | Sale | $17,471 | -39 | -0.16% | $447.98 | 24,076 | 18 Aug 2025 | Direct | F2, F3 |
| transaction | ALNY | Common Stock | Sale | $40,493 | -90 | -0.37% | $449.92 | 23,986 | 18 Aug 2025 | Direct | F2, F4 |
| transaction | ALNY | Common Stock | Sale | $17,586 | -39 | -0.16% | $450.92 | 23,947 | 18 Aug 2025 | Direct | F2, F5 |
| transaction | ALNY | Common Stock | Sale | $46,555 | -103 | -0.43% | $451.99 | 23,844 | 18 Aug 2025 | Direct | F2, F6 |
| transaction | ALNY | Common Stock | Sale | $149,024 | -329 | -1.4% | $452.96 | 23,515 | 18 Aug 2025 | Direct | F2, F7 |
| transaction | ALNY | Common Stock | Sale | $246,544 | -543 | -2.3% | $454.04 | 22,972 | 18 Aug 2025 | Direct | F2, F8 |
| transaction | ALNY | Common Stock | Sale | $109,616 | -241 | -1% | $454.84 | 22,731 | 18 Aug 2025 | Direct | F2, F9 |
| transaction | ALNY | Common Stock | Sale | $5,470 | -12 | -0.05% | $455.82 | 22,719 | 18 Aug 2025 | Direct | F2, F10 |
| holding | ALNY | Common Stock | 537 | 15 Aug 2025 | by Managed Account | F11 |
| Id | Content |
|---|---|
| F1 | On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the achievement of a clinical milestone, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on August 15, 2025. |
| F2 | Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024. |
| F3 | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.53 to $448.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F4 | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.21 to $450.16. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F5 | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.42 to $451.39. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F6 | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.48 to $452.48. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F7 | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.49 to $453.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F8 | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.50 to $454.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F9 | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.58 to $455.55. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F10 | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.65 to $456.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F11 | Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program. |